Drug Trial Radar · NCT04771273
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)
Last checked: Nov 19, 2026Latest source record: Dec 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
295
Actual
Start
Apr 27, 2021
Primary completion
Nov 9, 2023
Study completion Dec 21, 2023
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open for men and women with a liver disease called nonalcoholic steatohepatitis (NASH) and liver fibrosis. The purpose of the study is to find out whether a medicine called BI 456906 helps patients with NASH and liver fibrosis. The study tests 3 different doses of BI 456906 to find the dose that helps best. Participants are put into 4 groups randomly, which means by chance. There are 3 groups that each receive a different dose of BI 456906 and there is 1 group that receives placebo. BI 456906 and placebo are given as an injection under the skin once per week. The placebo injection looks like the BI 456906 injection but does not contain any medicine. Participants are in the study for a little over 1 year (60 weeks). During this time, they visit the study site several times and have some video calls in addition. At the visits, the study doctors take different measurements. To see whether the treatment works, the doctors take a very small sample of liver tissue (biopsy) from each participant at the start and at the end of the study. They also examine the liver by ultrasound and MRI. The doctors also regularly check the general health of the participants.
Conditions
- Non-alcoholic Steatohepatitis (NASH)
Interventions
SurvodutideDrug
Survodutide
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Actual Maintenance TreatmentTime frame: At baseline and at 48 weeks.
- Improvement (Yes/ no) From Baseline in Liver Histological Findings Based on Liver Biopsy After 48 Weeks of Treatment in Patients With NASH (NAS ≥ 4, Fibrosis F1-F3) - Planned Maintenance TreatmentTime frame: At baseline and after 48 weeks of treatment.
Locations
154 sites in 25 countries. Site status is shown where the registry gives one.
North Alabama Health Research, LLC
Huntsville, Alabama
Southern California Research Center
Coronado, California
Velocity Clinical Research
Huntington Park, California
Velocity Clinical Research
Panorama City, California
Quest Clinical Research
San Francisco, California
Peak Gastroenterology Associates
Colorado Springs, Colorado
Integrity Clinical Research, LLC
Doral, Florida
Covenant Metabolic Specialists, LLC
Fort Myers, Florida
Optimus U Corporation
Miami, Florida
Sanchez Clinical Research ,Inc
Miami, Florida
Ocala GI Research
Ocala, Florida
Omega Research Orlando, LLC
Orlando, Florida
Covenant Metabolic Specialists, LLC
Sarasota, Florida
Gastrointestinal Specialists of Georgia
Marietta, Georgia
Digestive Research Alliance of Michiana
South Bend, Indiana
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Delta Research Partners, LLC
Bastrop, Louisiana
Centex Studies, Inc.
Lake Charles, Louisiana
Tandem Clinical Research
Marrero, Louisiana
NECCR PrimaCare Research, LLC
Fall River, Massachusetts
National Diabetes and Obesity Research Institute
Biloxi, Mississippi
Gastrointestinal Associates
Flowood, Mississippi
AIG Digestive Disease Research
Florham Park, New Jersey
Northeast GI Research Division
Concord, North Carolina
Lucas Research, Inc.
Morehead City, North Carolina
Digestive Diseases Research Center
Greenwood, South Carolina
Palmetto Clinical Research
Summerville, South Carolina
Digestive Health Research, LLC
Hermitage, Tennessee
Texas Clinical Research Institute, LLC
Arlington, Texas
Texas Liver Institute
Austin, Texas
South Texas Research Institute
Brownsville, Texas
South Texas Research Institute
Edinburg, Texas
Houston Methodist Hospital
Houston, Texas
American Research Corporation at the Texas Liver Institute
San Antonio, Texas
Pinnacle Clinical Research
San Antonio, Texas
Virginia Commonwealth University
Richmond, Virginia
Gold Coast University Hospital
Southport, Queensland, Australia
Monash Medical Centre
Clayton, Victoria, Australia
Royal Melbourne Hospital
Parkville, Victoria, Australia
Medical University of Graz State Hospital - University Hospital Graz
Graz, Austria
Showing 40 of 154 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.